N-Terminal domain antiandrogen

{{DISPLAYTITLE:N-Terminal domain antiandrogen}}

{{See also|Discovery and development of antiandrogens#N-Terminal domain antagonists}}

{{Infobox drug class

| Image = EPI-001.svg

| ImageClass = skin-invert-image

| Alt =

| Caption = EPI-001, the first major N-terminal domain AR antagonist to be developed.

| Width = 250px

| Synonyms = N-Terminal domain AR antagonists; AR NTD antagonists

| Use = Prostate cancer

| ATC_prefix =

| Biological_target = Androgen receptor

| Chemical_class =

| Drugs.com =

| Consumer_Reports =

| medicinenet =

| rxlist =

| MeshID =

}}

N-Terminal domain antiandrogens are a novel type of antiandrogen that bind to the N-terminal domain of the androgen receptor (AR) instead of the ligand-binding domain (where all currently-available antiandrogens bind) and disrupt interactions between the AR and its coregulatory binding partners, thereby blocking AR-mediated gene transcription. They are being investigated for the treatment of prostate cancer.